Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL185561 | 0.76 | — | — | |
| SCHEMBL22436525 | 0.74 | PTPN1 (0.41) | KDM4EALDH1A1LMNAHPGDTDP1 | |
| Hydrochloric Acid SCHEMBL22436543 | 0.74 | PTPN1 (0.41) | KDM4EALDH1A1LMNAHPGDTDP1 | |
| SCHEMBL3355222 | 0.74 | — | — | |
| Potassium Ion SCHEMBL20532960 | 0.72 | DPP4 (0.36) | DPP4DPP8DPP7 | |
| SCHEMBL15114293 | 0.71 | ELANE (0.33) | KDM4EALDH1A1LMNAHPGDTDP1 | |
| Potassium Ion SCHEMBL31377889 | 0.68 | NPC1 (0.35) | HSD17B10 | |
| SCHEMBL21682411 | 0.68 | LIPG (0.33) | — | |
| SCHEMBL15728533 | 0.67 | KCNE1 (0.40) | KDM4EALDH1A1LMNADPP4DPP8 | |
| SCHEMBL10299634 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3833672-B1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE SRL (IT) | 2024-09-18 | — | — | EP | disclosed |
| US-20240287070-A1 | FUSED HETEROCYCLIC DERIVATIVES | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2024-08-29 | — | — | US | disclosed |
| EP-4347590-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2024-04-10 | — | — | EP | disclosed |
| CN-117715909-A | Condensed heterocyclic derivative | 杨森科学爱尔兰无限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-113272309-B | Tricyclic inhibitors of hepatitis b virus | 圣拉斐尔医院有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-117447375-A | Guanidine compound, preparation method and application thereof | 中国医学科学院药物研究所 | 2024-01-26 | — | — | CN | disclosed |
| US-20230076319-A1 | INHIBITORS OF HEPATITIS B VIRUS | ANTIOS THERAPEUTICS INC (US) | 2023-03-09 | — | — | US | disclosed |
| WO-2022253259-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-12-08 | — | — | WO | disclosed |
| US-11504382-B2 | Tricyclic inhibitors of Hepatitis B virus | Antios Therapeutics, Inc. (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220110943-A1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2022-04-14 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
| WO-2009117540-A1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-24 | — | — | WO | disclosed |
| EP-2102169-A1 | INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | AstraZeneca AB (SE) | 2009-09-23 | — | — | EP | disclosed |
| WO-2009082819-A1 | NOVEL LUPANE DERIVATIVES | VIROCHEM PHARMA INC. (CA) | 2009-07-09 | — | — | WO | disclosed |
| US-20090035324-A1 | NOVEL PYRIMIDINECARBOXAMIDE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| WO-2009009531-A2 | PYRIMIDINECARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF HIV INFECTIONS | CONCERT PHARMACEUTICALS INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20080214641-A1 | Chemical compounds 572 | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | US | disclosed |
| WO-2008076048-A1 | INDAZOLYL ESTER AND AMIDE DERIVATIVES FOR THE TREATMENT OF GLUCOCORTICOID RECEPTOR MEDIATED DISORDERS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| WO-2007143446-A1 | SPIRO-CONDENSED HETEROTRICYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-13 | — | — | WO | disclosed |
| US-20070281917-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214641-A1 | Chemical compounds 572 | ABCG2, ABCB1, CYP11B2 | KDM4E 2848/4885ALDH1A1 699/4885LMNA 1618/4885 |
| US-20240287070-A1 | FUSED HETEROCYCLIC DERIVATIVES | HAVCR2, HCCS, GOT2 | KDM4E 3515/4885ALDH1A1 2000/4885LMNA 723/4885 |
| US-11504382-B2 | Tricyclic inhibitors of Hepatitis B virus | HAVCR2, NR1H4, HCCS | KDM4E 1347/4885ALDH1A1 1104/4885LMNA 1438/4885 |
| US-20220110943-A1 | TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS | HAVCR2, NR1H4, HCCS | KDM4E 1347/4885ALDH1A1 1104/4885LMNA 1438/4885 |
| US-20090035324-A1 | NOVEL PYRIMIDINECARBOXAMIDE DERIVATIVES | TYMP, PNP, DPYD | KDM4E 1316/4885ALDH1A1 1435/4885LMNA 3558/4885 |
| US-20230076319-A1 | INHIBITORS OF HEPATITIS B VIRUS | HAVCR2, HDGF, SLC10A1 | KDM4E 1410/4885ALDH1A1 1035/4885LMNA 2132/4885 |
| US-20070281917-A1 | HIV Integrase Inhibitors | TYMP, POLN, IMPDH1 | KDM4E 680/4885ALDH1A1 301/4885LMNA 947/4885 |
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | KDM4E 1609/4885ALDH1A1 539/4885LMNA 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.